Manning & Napier Group's ABBV Position Overview
Manning & Napier Group (via Manning & Napier Advisors LLC) currently holds 356 shares of AbbVie Inc. (ABBV) worth $81,787, representing 0.00% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 48 quarters.
Based on 13F filings since 2013, Manning & Napier Group has maintained a long-term strategic position in ABBV, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2016, adding 159,258 shares. Largest reduction occurred in Q3 2025, reducing 440,302 shares.
Analysis based on 13F filings available since 2013 Q2
Manning & Napier Group's AbbVie (ABBV) Holding Value Over Time
Track share changes against reported price movement
Quarterly AbbVie (ABBV) Trades by Manning & Napier Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +92 | Add 34.85% | 356 | $229.74 |
| Q3 2025 | +264 | New Buy | 264 | $231.54 |
| Q2 2021 | -440,566 | Sold Out | 440,566 | $108.22 |
| Q1 2021 | +8,491 | Add 1.97% | 440,566 | $108.22 |
| Q4 2020 | -27,966 | Reduce 6.08% | 432,075 | $107.15 |
| Q3 2020 | +6,262 | Add 1.38% | 460,041 | $87.59 |
| Q2 2020 | -3,372 | Reduce 0.74% | 453,779 | $98.18 |
| Q1 2020 | -2,773 | Reduce 0.60% | 457,151 | $76.19 |
| Q4 2019 | +38,385 | Add 9.11% | 459,924 | $88.54 |
| Q3 2019 | +2,250 | Add 0.54% | 421,539 | $75.72 |
| Q2 2019 | +39,969 | Add 10.54% | 419,289 | $72.72 |
| Q1 2019 | +83,583 | Add 28.26% | 379,320 | $80.59 |
| Q4 2018 | +9,118 | Add 3.18% | 295,737 | $92.19 |
| Q3 2018 | +20,976 | Add 7.90% | 286,619 | $94.57 |
| Q2 2018 | -10,003 | Reduce 3.63% | 265,643 | $92.64 |
| Q1 2018 | +40,902 | Add 17.42% | 275,646 | $94.65 |
| Q4 2017 | +234,745 | Add 0.00% | 234,744 | $96.71 |
| Q3 2017 | -3,120 | Reduce 1.21% | 254,936 | $88.85 |
| Q2 2017 | +89,903 | Add 53.46% | 258,056 | $72.50 |
| Q1 2017 | +7,427 | Add 4.62% | 168,153 | $65.15 |
| Q4 2016 | +3,183 | Add 2.02% | 160,726 | $62.60 |
| Q3 2016 | -1,715 | Reduce 1.08% | 157,543 | $63.06 |
| Q2 2016 | +159,258 | New Buy | 159,258 | $61.90 |
| Q2 2015 | -187,414 | Sold Out | 0 | $0.00 |
| Q1 2015 | -37 | Reduce 0.02% | 187,414 | $58.53 |
| Q4 2014 | +1,363 | Add 0.73% | 187,451 | $65.44 |
| Q3 2014 | -5,941 | Reduce 3.09% | 186,088 | $57.75 |
| Q2 2014 | +45,952 | Add 31.46% | 192,029 | $56.43 |
| Q1 2014 | -2,988 | Reduce 2.00% | 146,077 | $51.39 |
| Q4 2013 | -78,592 | Reduce 34.52% | 149,065 | $52.80 |
| Q3 2013 | +1,463 | Add 0.65% | 227,657 | $44.72 |
| Q2 2013 | +226,194 | Add 0.00% | 226,194 | $41.33 |
Manning & Napier Group's AbbVie Investment FAQs
Manning & Napier Group first purchased AbbVie Inc. (ABBV) in Q2 2013, acquiring 226,194 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Manning & Napier Group has held AbbVie Inc. (ABBV) for 48 quarters since Q2 2013.
Manning & Napier Group's largest addition to AbbVie Inc. (ABBV) was in Q4 2017, adding 234,744 shares worth $22.7 M.
According to the latest 13F filing for Q4 2025, Manning & Napier Group's firm, Manning & Napier Advisors LLC, owns 356 shares of AbbVie Inc. (ABBV), valued at approximately $81,787.
As of the Q4 2025 filing, AbbVie Inc. (ABBV) represents approximately 0.00% of Manning & Napier Group's publicly disclosed stock portfolio, making it one of their key holdings.
Manning & Napier Group's peak holding in AbbVie Inc. (ABBV) was 460,041 shares, as reported at the end of Q3 2020.